Increased level of phosphorylated ShcA measured by chemiluminescence-linked immunoassay is a predictor of good prognosis in primary breast cancer expressing low levels of estrogen receptor

Cancers

Volumn 2, Issue 1, 2010, Pages 153-164

  Cicenas, Jonas ^a,b   Küng, Willy ^b   Eppenberger, Urs ^a   Eppenberger Castori, Serenella ^a,c  

^a Stiftung Tumorbank Basel   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Biomarker; Breast cancer; Estrogen receptor; Immunoassay; Kinase; Phosphorylation; ShcA

Indexed keywords

ADAPTOR PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROTEIN SHCA; SERINE; THREONINE; TYROSINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CHEMOLUMINESCENCE; CONTROLLED STUDY; CYTOSOL; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FROZEN SECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS;

EID: 79952122324     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2010153     Document Type: Article

References (21)

1. Cicenas, J.; Urban, P.; Küng, W.; Vuaroqueaux, V.; Labuhn, M.; Wight, E.; Eppenberger, U.; Eppenberger-Castori, S. Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res. 2005, 7, R394-R401.
2. Cicenas, J.; Urban, P.; Vuaroqueaux, V.; Labuhn, M.; Küng, W.; Wight, E.; Mayhew, M.; Eppenberger, U.; Eppenberger-Castori, S. Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur. J. Cancer 2006, 42, 636-645.
3. Bonfini, L.; Migliaccio, L.; Pelicci, G; Lanfrancone, L.; Pelicci P.G. Not all Shc's roads lead to Ras. Trends Biochem. Sci. 1996, 21, 257-261.
4. Marshall, M.S. Ras target proteins in eukaryotic cells. FASEB 1995, 91, 311-318.
5. Salcini AE, McGlade J, Pelicci G, Nicoletti I, Pawson TP, Pelicci PG. Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins. Oncogene 1994, 9, 2827-2836.
6. Gotoh, N.; Toyoda, M.; Shibuya, M. Tyrosine phosphorylation sites at amino acids 239 and 240 of Shc are involved in epidermal growth factor-induced mitogenic signalling that is distinct from Ras/mitogen-activated protein kinase activation. Mol. Cell Biol. 1997, 17, 1824-1831.
7. Lanfrancone, L.; Pelicci, G. Brizzi, M.F.; Aronica, M.G.; Casciari, C.; Giuli, S.; Pegoraro, L.; Pawson, T.; Pelicci, P.G.; Arouica, M.G. Overexpression of Shc proteins potentiates the proliferative response to the granulocyte-macrophage colony-stimulating factor and recruitment of Grb2/SoS and Grb2/p140 complexes to the beta receptor subunit. Oncogene 1995, 10, 907-917.
8. Lai, K.M.; Pawson, T. The ShcA phosphotyrosine docking protein sensitizes cardiovascular signalling in the mouse embryo. Genes Dev. 2000, 14, 1132-1145.
9. Migliaccio, E.; Mele, S.; Salcini, A.E.; Pelicci, G.; Lai, K.M.; Superti-Furga, G.; Pawson, T.; Di Fiore, P.P.; Lanfrancone, L.; Pelicci, P.G. Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. EMBO J. 1997, 16, 706-716.
10. Okada, S.; Kao, A.W.; Ceresa, B.P.; Blaikie, P.; Margolis, B.; Pessin, J.E. The 66-kDa Shc isoform is a negative regulator of the epidermal growth factor-stimulated mitogen-activated protein kinase pathway. J. Biol. Chem. 1997, 272, 28042-28049.
11. Le, S.; Connors, T.J.; Maroney, A.C. c-Jun N-terminal kinase specifically phosphorylates p66ShcA at serine 36 in response to ultraviolet irradiation. J. Biol. Chem. 2001, 276, 48332-48336.
12. Cicenas, J. The potential role of Akt phosphorylation in human cancers. Int. J. Bio. Markers 2008, 23, 1-9.
13. Wu, Y.; Mohamed, H.; Chillarm, R.; Ali, I.; Clayton, S.; Slamon, D.; Vadgama, J.V. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res. 2008, 10, R3-R22.
14. Cicenas, J. The potential role of the EGFR/ERBB2 heterodimer in breast cancer. Expert. Opin. Ther. Pat. 2007, 17, 607-616.
15. Xia, W.; Chen, J.S.; Zhou, X.; Sun, P.R.; Lee, D.F.; Liao, Y.; Zhou, B.P.; Hung, M.C. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin. Cancer Res. 2004, 10, 3815-3824.
16. R.B. p27KIP1 phosphorylation by PKB/Akt leads to poor breast cancer prognosis. Breast Cancer Res. 2003, 5, 162-163.
17. Eppenberger-Castori, S.; Kueng, W.; Benz, C.; Caduff, R.; Varga, Z.; Bannwart, F.; Fink, D.; Dieterich, H.; Hohl, M.; Müller H., et al. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J. Clin. Oncol. 2001, 19, 645-656.
18. Milde-Langosch, K.; Bamberger, A.M.; Rieck, G.; Grund, D.; Hemminger, G.; Müller, V.; Löning, T. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br. J. Cancer 2005, 92, 2206-2215.
19. Svensson, S.; Jirström, K.; Rydén, L.; Roos, G.; Emdin, S.; Ostrowski, M.C.; Landberg, G. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumors with good prognosis. Oncogene 2005, 24, 4370-4379.
20. Bergqvist, J.; Elmberger, G.; Ohd, J.; Linderholm, B.; Bjohle, J.; Hellborg, H.; Nordgren, H.; Borg, A.L.; Skoog, L.; Bergh, J. Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. Eur. J. Cancer 2006, 42, 1104-1112.
21. Schmitt, M.; Mengele, K.; Schueren, E.; Sweep, F.C.; Foekens, J.A.; Brünner, N.; Laabs, J.; Malik, A.; Harbeck, N.; European Organisation for Research and Treatment of Cancer Pathobiology Group. European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers. Eur. J. Cancer 2007, 43, 835-844.